DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Frequently asked questions
What sector does DiaMedica Therapeutics Inc (DMAC) operate in?
DiaMedica Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is DiaMedica Therapeutics Inc (DMAC) current stock price?
As of the latest data, DiaMedica Therapeutics Inc stock price is $8.48, with a previous close of $8.74. DiaMedica Therapeutics Inc lost -$0.26 in the last trading session, representing a -2.97% loss.
What is DiaMedica Therapeutics Inc (DMAC) current market capitalization?
DiaMedica Therapeutics Inc market cap is approximately 457.29 million.
What is DiaMedica Therapeutics Inc (DMAC) Earnings Per Share (EPS)?
The trailing EPS is -$0.72, and the forward EPS is -$0.81.
What is DiaMedica Therapeutics Inc (DMAC) EBITDA?
DiaMedica Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -10.12 million.
Does DiaMedica Therapeutics Inc (DMAC) pay dividends?
No. DiaMedica Therapeutics Inc does not pay a dividend.
When is DiaMedica Therapeutics Inc (DMAC) next earnings report?
DiaMedica Therapeutics Inc is expected to release its next earnings report on September 30, 2026.
What is DiaMedica Therapeutics Inc (DMAC) beta (volatility) score?
DiaMedica Therapeutics Inc has a beta of 0.914, meaning its volatility is roughly in line with the market.
